C4 Therapeutics
CCCC
107 hedge funds and large institutions have $1.21B invested in C4 Therapeutics in 2021 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 43 increasing their positions, 14 reducing their positions, and 12 closing their positions.
207% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 14
200% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 12
30% more capital invested
Capital invested by funds: $927M → $1.21B (+$282M)
29% more funds holding
Funds holding: 83 → 107 (+24)
15.75% more ownership
Funds ownership: 58.2% → 73.95% (+16%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$51.8M |
| 2 |
BlackRock
New York
|
+$51.5M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$41M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.5M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$19.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$76.5M |
| 2 |
PA
Perceptive Advisors
New York
|
-$32.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.82M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$5.82M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$5.18M |
CCCC Hedge Fund Activity: Q2 2021 in Review
107 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q2 2021, worth a combined $1.21B — up 30% from $927M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CCCC positions and 12 closed out — a net gain of 24 holders — while 43 added to existing stakes and 14 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $51.8M. The largest seller was Cormorant Asset Management, cutting an estimated $76.5M.
- 107 institutional investors held C4 Therapeutics (CCCC) as of Q2 2021, up from 83 in Q1 2021.
- Funds reported $1.21B of C4 Therapeutics stock for Q2 2021, up 30% quarter-over-quarter.
- 36 funds opened new C4 Therapeutics positions in Q2 2021 and 12 closed out, a net change of +24 holders.
- The largest C4 Therapeutics buyer in Q2 2021 was T. Rowe Price Associates, an estimated $51.8M added.
- The largest C4 Therapeutics seller in Q2 2021 was Cormorant Asset Management, an estimated $76.5M sold.
Based on aggregated 13F filings for Q2 2021.